Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

VIVUS Launches QSYMIA in the United Arab Emirates

Published on 03/10/2025 at 06:00 am EDT

S&P Capital IQ

VIVUS, INC.

+1.56%

VIVUS LLC announced the market approval of QSYMIA (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE) for treatment of overweight and obesity in adults and pediatric patients, age 12 and older. The UAE is the first country in the Middle East region to approve QSYMIA and have it available in market. This marks an important milestone for patients challenged by obesity and the physicians who treat them.VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this epidemic in line with the UAE vision to address obesity.

Alphamed Drug Store is the exclusive distributor of QSYMIA in the UAE. The World Obesity Federation estimates that by 2035, approximately 7.5 million adults, children, and adolescents in the UAE will be overweight or living with obesity. This statistic underscores the severity of the obesity challenge in the UAE, revealing potential detrimental effects on the health of affected individuals and the nation's economy, now and in the foreseeable future.

Obesity is forecasted to affect one billion individuals globally by 2030, nearly double that in 2020. In response to the substantial health and economic burdens of the obesity epidemic, VIVUS is expanding access to QSYMIA to patients in multiple European countries, which will be sold under the trade name QSIVA (phentermine and topiramate modified-release). VIVUS plans to provide access to QSYMIA to over one billion individuals worldwide by the end of 2025.

QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Latest news about VIVUS, Inc.

Mar. 10	Vivus Bv, A Subsidiary of Vivus Llc Announces Qsiva Price Reduction Across Nordics and Poland	CI
Jan. 26	VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA	CI
Jan. 07	VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii	CI
25-09-04	VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome	CI
25-05-27	VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide	CI
25-04-14	VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma	CI
25-03-10	VIVUS Launches QSYMIA in the United Arab Emirates	CI
24-10-23	VIVUS Announces Label Update for QSYMIA	CI
24-05-30	Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	CI
24-04-22	VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	CI
23-11-28	VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	CI
23-01-10	VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	CI
22-07-20	FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	CI
20-12-10	VIVUS, Inc. Emerged from Bankruptcy	CI
20-12-10	Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	CI

Chart VIVUS, Inc.

Duration

Period

VVUSQ: Dynamic Chart

Company Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Employees

Sector

Pharmaceuticals

More about the company